![\"\"](\"https:\/\/www.iths.org\/course-instructors\/wp-content\/uploads\/sites\/31\/2019\/02\/eaton-1.png\")
<\/p>\n<\/p>\n
Associate Professor, School of Medicine<\/em> Dr. Keith D. Eaton is a medical oncologist specializing in thoracic and head and neck cancers at the University of Washington\/Seattle Cancer Care Alliance. He received his undergraduate degree in physics and mathematics from the University of California, Berkley and went on to pursue a doctorate in physics at the University of California, San Diego. While in graduate school, he decided to change direction and pursue a career in medicine and completed his Ph. D and M.D. at UCSD.<\/p>\n He currently serves as the Medical Director of Quality, Safety and Value, Medical Director of Infusion and Pharmacy, and Clinical Director of the Thoracic, Head and Neck Oncology programs at the Seattle Cancer Care Alliance. In addition to his clinical and administrative roles, Dr. Eaton is an active clinical investigator and has been a principal investigator for over twenty trials, including industry sponsored trials, investigator initiated trials, and NIH funded research. His research interests are in immunotherapy, molecular targeted therapies, and quality improvement.<\/p>\n In November 2012, Dr. Eaton was diagnosed with leukemia and found himself in a new role of patient and clinical trial subject. He went through multiple rounds of chemotherapy before receiving CAR T-Cell therapy at the University of Pennsylvania. After receiving this form of immunotherapy, his cancer was reduced to undetectable levels. He subsequently underwent a stem cell transplant and has returned to a healthy life.<\/p>\n Keith Eaton, MD, PhD Associate Professor, School of Medicine University of Washington Associate Member Fred Hutchinson Cancer Research Center Medical Director, Quality, Safety and Value, Infusion and Pharmacy Services; Clinical Director,\u00a0Thoracic\/Head & Neck Oncology Seattle Cancer Care Alliance Dr. Keith D. Eaton is a medical…<\/p>\n","protected":false},"author":2,"featured_media":611,"parent":97,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_custom_body_class":"","_custom_post_class":"","footnotes":""},"class_list":["post-610","page","type-page","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/www.iths.org\/cc\/wp-json\/wp\/v2\/pages\/610","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.iths.org\/cc\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.iths.org\/cc\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.iths.org\/cc\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.iths.org\/cc\/wp-json\/wp\/v2\/comments?post=610"}],"version-history":[{"count":3,"href":"https:\/\/www.iths.org\/cc\/wp-json\/wp\/v2\/pages\/610\/revisions"}],"predecessor-version":[{"id":733,"href":"https:\/\/www.iths.org\/cc\/wp-json\/wp\/v2\/pages\/610\/revisions\/733"}],"up":[{"embeddable":true,"href":"https:\/\/www.iths.org\/cc\/wp-json\/wp\/v2\/pages\/97"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.iths.org\/cc\/wp-json\/wp\/v2\/media\/611"}],"wp:attachment":[{"href":"https:\/\/www.iths.org\/cc\/wp-json\/wp\/v2\/media?parent=610"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nUniversity of Washington
\nAssociate Member<\/em>
\nFred Hutchinson Cancer Research Center
\nMedical Director, Quality, Safety and Value, Infusion and Pharmacy Services; Clinical Director,\u00a0Thoracic\/Head & Neck Oncology<\/em>
\nSeattle Cancer Care Alliance<\/p>\n<\/div>\nLearn More<\/h4>\n
\n